A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Thrombin clotting Time : 883
Test CodeTCT or 883
CPT Codes
85670
Transport Container
1 mL frozen platelet-poor plasma collected in 3.2% sodium citrate (light blue-top) tube (Min: 0.5 mL)
Submit a separate, frozen vial for each special coagulation assay ordered. Draw blood in a light blue-top tube containing 3.2% sodium citrate. Mix gently by inverting 3-4 times. Centrifuge 15 minutes at 1500g within one hour of collection. Using a plastic pipette, remove plasma, taking care to avoid the WBC/platelet buffy layer and place into a plastic vial. Centrifuge a second time and transfer platelet-poor plasma into a new plastic vial. Freeze immediately and transport on dry ice.
Submit a separate, frozen vial for each special coagulation assay ordered. Draw blood in a light blue-top tube containing 3.2% sodium citrate. Mix gently by inverting 3-4 times. Centrifuge 15 minutes at 1500g within one hour of collection. Using a plastic pipette, remove plasma, taking care to avoid the WBC/platelet buffy layer and place into a plastic vial. Centrifuge a second time and transfer platelet-poor plasma into a new plastic vial. Freeze immediately and transport on dry ice.
Transport Temperature
Frozen
Specimen Stability
Room temperature: Unacceptable; Refrigerated: Unacceptable; Frozen: 30 days
Methodology
Clot detection
FDA Status
FDA
Setup Schedule
Monday - Saturday
Report Available
1-3 days
Reference Range
13-19 seconds
Clinical Significance
Thrombin clotting time is useful for evaluating the presence of heparin and other direct thrombin inhibitor anticoagulants in specimens with prolonged coagulation studies. It is also used to aid in the diagnosis of congenital and acquired disorders of fibrinogen.
Anticoagulant interference: Expected impact by therapeutic levels (potential interference depends upon drug concentration):
• Vitamin K antagonists (e.g., warfarin) - no effect
• Heparin (UFH or LMWH) – prolonged
• Dabigatran or Argatroban (direct thrombin inhibitors) – prolonged
• Rivaroxaban, Apixaban, Edoxaban (Factor Xa Inhibitors) - no effect
Anticoagulant interference: Expected impact by therapeutic levels (potential interference depends upon drug concentration):
• Vitamin K antagonists (e.g., warfarin) - no effect
• Heparin (UFH or LMWH) – prolonged
• Dabigatran or Argatroban (direct thrombin inhibitors) – prolonged
• Rivaroxaban, Apixaban, Edoxaban (Factor Xa Inhibitors) - no effect
Performing Laboratory
med fusion